A recent study on Huonslab’s Hydiffuze technology has found that the pharmaceutical product demonstrated enhanced bioavailability of subcutaneous infliximab has been selected as a poster presentation at the American Association for Cancer Research...
Huonslab, a subsidiary of Huons Global and a major player in recombinant human hyaluronidase-based biologics Sub-Q delivery, announced on Nov. 11 that it has completed patent filing and examination requests for its recombinant human hyaluronidase...
Huonslab is accelerating the development of a drug that uses Hydiffuze to enhance patient convenience in subcutaneous injections (SC).
Huonslab's HLB3-002, a genetic recombinant hyaluronidase candidate, has been approved for clinical trials, with potential applications in cosmetic procedures, dermatology, pain and edema treatment.
The research subsidiary of biopharmaceutical firm Huons Global said it has filed for a patent on the manufacturing method of its human genetic recombinant hyaluronidase candidate.
Huonslab's HLB3-002, a human genetic recombinant hyaluronidase candidate, produced meaningful results confirming its efficacy, the Korean company said Tuesday.
Korea JoongAng Daily Sitemap
